Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Deucravacitinib in Moderate Plaque Psoriasis
2023-509738-20-00Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 4, randomised, single-blind trial of risankizumab and deucravacitinib in plaque psoriasis (2 arms), sponsored by AbbVie Inc. Primary endpoints: PASI 100 response at Week 16 (Period A), sPGA 0 with at least 2-grade improvement from baseline at Week 16 (Period A) and 1 more. Started Jul 2024; status: completed.
02
Drugs
risankizumabdeucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-509738-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509738-20-00.